How does the new 57-77 million annual agitation episodes estimate impact IGALMI®'s market potential?

The new estimate of 57-77 million annual agitation episodes significantly impacts the market potential for IGALMI® (dexmedetomidine) sublingual film, particularly for its investigational at-home use (BXCL501). This revised figure represents a substantial increase from BioXcel Therapeutics' previous estimate of 23 million annual episodes.1

Here's a breakdown of the impact:

• Expanded Addressable Market: IGALMI® is approved for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults, administered under healthcare supervision.2 BioXcel Therapeutics is also developing BXCL501, the same drug, for at-home use in these indications and for agitation associated with Alzheimer’s dementia.2 The new estimate of 57-77 million episodes annually for at-home agitation suggests a much larger potential patient population for BXCL501, should it receive regulatory approval for this setting.1
• Underestimation of Previous Data: The company attributes the difference to the nature of the previous 23 million estimate, which was based on historical claims data reflecting approximately 1.2 episodes per patient per month.3 BioXcel Therapeutics believes these claims data likely underestimated the true frequency of agitation episodes due to a lack of approved at-home treatment options.1
• Market Research Insights: The updated estimate is supported by market research indicating approximately 3 episodes of agitation per month in the home setting.4
• Increased Commercial Opportunity: BioXcel Therapeutics' CEO, Vimal Mehta, has highlighted that this new estimate points to a "target addressable market meaningfully larger than our original estimate" and an "opportunity to expand the market potential of IGALMI® and bring this drug to millions of additional patients."2 This suggests a considerable upside for the company's revenue potential if BXCL501 successfully penetrates the at-home market.

In essence, the higher estimate of annual agitation episodes indicates a significantly larger unmet medical need in the at-home setting, thereby increasing the potential commercial opportunity for IGALMI® (BXCL501) if it secures approval for this expanded use.